Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.47 |
| ▸ | ITGB1 | P05556 | 10/20 | 0.47 |
| ▸ | ITGAV | P06756 | 10/20 | 0.47 |
| ▸ | ITGA5 | P08648 | 10/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 10/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.42 |
| ▸ | ITGA4 | P13612 | 3/20 | 0.41 |
| ▸ | YAP1 | P46937 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12005388 | 0.94 | ITGB3 (0.41) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL12005819 | 0.89 | EGLN1 (0.49) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL12006464 | 0.89 | CKS1B (0.36) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL12002461 | 0.87 | CKS1B (0.38) | MAPT | |
| SCHEMBL12002581 | 0.87 | EGLN1 (0.44) | MAPT | |
| SCHEMBL12005870 | 0.86 | ITGB3 (0.37) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL12006136 | 0.86 | ITGB3 (0.39) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL1774381 | 0.86 | ITGB3 (0.41) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL12005996 | 0.86 | ITGB3 (0.38) | ITGB3ITGB1ITGAVITGA5ITGB5 | |
| SCHEMBL12782219 | 0.85 | ACHE (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785462-B2 | 5-hydroxypyrimidine-4-carboxamide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220609-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE DERIVATIVE | EPOR, EGLN2, EGLN1 | ITGB3 4004/4885ITGB1 3461/4885ITGAV 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.